Author + information
- Received June 1, 2000
- Revision received November 14, 2000
- Accepted December 15, 2000
- Published online April 1, 2001.
- Takayoshi Tsutamoto, MDa,* (, )
- Atsuyuki Wada, MDa,
- Keiko Maeda, MDa,
- Naoko Mabuchi, MDa,
- Masaru Hayashi, MDa,
- Takashi Tsutsui, MDa,
- Masato Ohnishi, MDa,
- Masahide Sawaki, MDa,
- Masanori Fujii, MDa,
- Takehiro Matsumoto, MDa,
- Toshiki Matsui, MDa and
- Masahiko Kinoshita, MDa
- ↵*Reprint requests and correspondence: Dr. Takayoshi Tsutamoto, First Department of Internal Medicine, Shiga University of Medical Science, Tsukinowa, Seta, Otsu 520-2192, Japan
We sought to evaluate the effects of spironolactone on neurohumoral factors and left ventricular remodeling in patients with congestive heart failure (CHF).
Aldosterone (ALD) promotes collagen synthesis and structural remodeling of the heart. Spironolactone, an ALD receptor antagonist, is reported to reduce mortality in patients with CHF, but its influence on left ventricular remodeling has not been clarified.
Thirty-seven patients with mild-to-moderate nonischemic CHF were randomly divided into two groups that received treatment with spironolactone (n = 20) or placebo (n = 17). We measured left ventricular volume and mass before treatment and after four months of treatment. We also measured the plasma levels of neurohumoral factors, such as atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), as well as plasma procollagen type III aminoterminal peptide (PIIINP), a marker of myocardial fibrosis.
Left ventricular volume and mass were significantly decreased and ejection fraction was significantly increased in the spironolactone group, while there were no changes in the placebo group. Plasma levels of ANP, BNP and PIIINP were significantly decreased after spironolactone treatment, but were unchanged in the placebo group. There was a significant positive correlation between the changes of PIIINP and changes of the left ventricular volume index (r = 0.45, p = 0.045) as well as the left ventricular mass index (r = 0.65, p = 0.0019) with spironolactone treatment.
These findings indicate that four months of treatment with spironolactone improved the left ventricular volume and mass, as well as decreased plasma level of BNP, a biochemical marker of prognosis and/or ventricular hypertrophy, suggesting that endogenous aldosterone has an important role in the process of left ventricular remodeling in nonischemic patients with CHF.
☆ Supported in part by Japanese Grants-in-Aid for Scientific Research (C).
- Received June 1, 2000.
- Revision received November 14, 2000.
- Accepted December 15, 2000.
- American College of Cardiology